source
- RevMed's pancreatic cancer drug Rasonque shows mixed results across KRAS subtypes, analysts stay optimisticFDA review documents revealed that Revolution Medicines' newly approved pancreatic cancer therapy, Rasonque, performed unevenly in a large subgroup of patients. The data highlight a lower objective…
- GSK to invest $800 million in new biologics manufacturing hub in PennsylvaniaGSK announced it will spend more than $800 million to expand its Upper Merion site near Philadelphia, adding biologics production capacity. The plan includes demolishing existing structures next y…